PhillyTablet Inquirer Daily News
Mobile
Home Delivery
philly.com
email
font size
comments
2
options
 
Monday, April 27, 2009

Wyeth's Ruffolo joins board of Trevena

A King of Prussia start-up drug discovery company called Trevena Inc. has added the retired president of R&D Wyeth Pharmaceuticals to its seven-member board of directors.

Robert R. Ruffolo Jr. joined the board of the privately held company after having been a member of its scientific advisory board only since January.

Little biotech often looks to land expertise from Big Pharma, and that's what Trevena has done. The board of Trevena, which raised $24 million in venture capital 13 months ago, had been composed of four of its venture investors, one Duke University representative, and its CEO, Maxine Gowen.

Trevena is working on treatments for cardiovascular and central nervous systems disorders. Its technology is licensed from Duke University Medical Center and based on research from the labs of Robert J. Lefkowitz and Howard A. Rockman.

In a statement, Ruffolo called the "science underway" at Trevena "tremendously exciting" and praised the management team as "first rate." He also said it was the first biotech board seat he's accepted since retiring from Wyeth less than a year ago.

Trevena currently has 21 employees, according to company spokesman Alastair Southwell.

 

 
Posted by Mike Armstrong @ 12:23 PM  Permalink | File Under: People | | Pharma, Biotech | 2 comments
Comments   
  • 0 like this / 0 don't   •   Posted 1:14 PM, 04/27/2009
    You spelled Ruffolo's name wrong twice in this article
    — WestPhilBornNRaised
  • 0 like this / 0 don't   •   Posted 3:46 PM, 04/27/2009
    Is that you will smith
    — cusoraider


2 comments
About Mike Armstrong
Mike Armstrong, a business editor and writer for nearly two decades, is the Inquirer's business columnist and PhillyInc blog editor. Contact Mike via e-mail or at 215-854-2980
Advertise Here